Mesoblast (MSB) Q4 2024 earnings summary

Executive summary

• Achieved significant progress in FDA engagement for three lead products, including BLA resubmission for RYONCIL in pediatric SR-aGVHD, with FDA review ongoing and PDUFA date set for January 7, 2025; commercial launch preparations underway.

• Proprietary allogeneic cell therapy platform with over 1,000 patents, covering major jurisdictions and extending exclusivity to at least 2037 for key products.

• Late-stage clinical pipeline includes RYONCIL for pediatric and adult GVHD, rexlemestrocel-L for chronic low back pain and heart failure, and REVASCOR for pediatric and adult heart failure.

• Advanced pivotal Phase 3 trials for rexlemestrocel-L in chronic low back pain and heart failure, with regulatory alignment and manufacturing readiness.

• Cost containment measures implemented, including payroll reductions and deferred management compensation.

Financial highlights

• Cash balance at June 30, 2024 was $63.3M, with an additional $10M available upon FDA approval of RYONCIL.

• Net operating cash usage reduced by 23% year-over-year to $48.5M for FY2024.

• Manufacturing expenditure reduced by $12M (43%) due to decreased inventory build and one-off prior year costs.

• Loss after tax for FY2024 was $88M; adjusted loss after tax was $78.3M, a $12.4M improvement year-over-year.

• Revenue for FY2024 was $5.9M, primarily from royalties on TEMCELL sales in Japan, down 17% from $7.1M in FY2023.

Outlook and guidance

• RYONCIL BLA resubmitted and accepted, with FDA PDUFA date set for January 7, 2025; commercial launch and market access activities underway.

• Second phase 3 trial for rexlemestrocel-L in chronic low back pain actively enrolling; expected to complete enrollment in 12 months, with a 12-month primary endpoint.

• Preparing for accelerated approval filing for REVASCOR in heart failure, following positive trial results.

• Focus on cost containment and prudent cash management to continue in FY2025.

• Plans to pursue label extension for RYONCIL in adults and further regulatory pathways for pipeline products.